Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genmab A/S ADR
(NQ:
GMAB
)
27.49
+0.30 (+1.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Genmab A/S ADR
< Previous
1
2
3
4
5
6
7
8
Next >
Kymera Therapeutics Stock Scores Rising Relative Price Strength
August 22, 2022
Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94.
Via
Investor's Business Daily
Where Genmab Stands With Analysts
August 11, 2022
Genmab (NASDAQ:GMAB) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Genmab, BioNTech Join Forces For Cancer Immunotherapy Candidates
August 05, 2022
Via
Benzinga
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
August 05, 2022
From
Genmab A/S
Via
Business Wire
Where Genmab Stands With Analysts
June 24, 2022
Analysts have provided the following ratings for Genmab (NASDAQ:GMAB) within the last quarter:
Via
Benzinga
AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial
June 13, 2022
Via
Benzinga
AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022
July 18, 2022
Via
Benzinga
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
July 18, 2022
From
Genmab A/S
Via
Business Wire
Is AbbVie Stock A Buy As Humira Biosimilar Rivals Loom?
July 07, 2022
Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.? Is AbbVie stock a buy today
Via
Investor's Business Daily
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
July 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Analyst Ratings for Genmab
May 12, 2022
Within the last quarter, Genmab (NASDAQ:GMAB) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022
June 24, 2022
Upgrades
Via
Benzinga
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium
June 11, 2022
From
Genmab
Via
Business Wire
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
June 06, 2022
From
Seagen Inc.
Via
Business Wire
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
June 06, 2022
From
Genmab A/S
Via
Business Wire
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022
From
Genmab
Via
Business Wire
Johnson & Johnson Stock: A Rare Bright Spot in the Market
May 14, 2022
JNJ stock is up on the year thanks in part to its steadily rising dividend, which investors covet during the current market volatility.
Via
InvestorPlace
Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress
May 12, 2022
From
Genmab
Via
Business Wire
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
May 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022
May 02, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
April 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study
April 14, 2022
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV)
Via
Benzinga
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
April 13, 2022
From
Genmab A/S
Via
Business Wire
BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines
April 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties
April 08, 2022
Via
Benzinga
Best Biotech Stocks To Buy In 2022
March 15, 2022
Biotechnology is the study of living creatures, biological systems, or derivatives to develop or improve healthcare products and therapies. This technology is connected with medical and...
Via
Talk Markets
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
February 24, 2022
From
Seagen Inc.
Via
Business Wire
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
February 24, 2022
From
Genmab A/S
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
January 31, 2022
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.